Candel wins FDA orphan drug designation for pancreatic cancer drug

Candel wins FDA orphan drug designation for pancreatic cancer drug

Submitted by admin on April 14, 2024 - 1:23pm
Source: 
Clinical Trials Arena
News Tags: 
FDA
Candel Therapeutics
CAN-2409
pancreatic cancer
orphan drugs
Headline: 
Candel wins FDA orphan drug designation for pancreatic cancer drug
snippet: 

The US Food and Drug Administration (FDA) has granted Candel Therapeutics’ immunotherapy candidate CAN-2409 (aglatimagene besadenovec) orphan drug designation for the treatment of pancreatic cancer.

Do Not Allow Advertisers to Use My Personal information